Clinical Research Papers:
Serological immune response against ADAM10 pro-domain is associated with favourable prognosis in stage III colorectal cancer patients
Metrics: PDF 808 views | HTML 965 views | ?
Sheila María Álvarez-Fernández1, Marco Barbariga1,5, Luca Cannizzaro1,6, Carlo Vittorio Cannistraci4, Laura Hurley1,7, Alan Zanardi1, Antonio Conti1, Francesca Sanvito2, Anna Innocenzi2, Nicolò Pecorelli3, Marco Braga3 and Massimo Alessio1
1 Proteome Biochemistry, IRCCS-San Raffaele Scientific Institute, Milan, Italy
2 Pathology, IRCCS-San Raffaele Scientific Institute, Milan, Italy
3 Department of Surgery, Vita-Salute San Raffaele University, Milan, Italy
4 Biomedical Cybernetics Group, Biotechnology Center (BIOTEC), Center for Molecular and Cellular Bioengineering (CMCB), Technische Universität Dresden, Dresden, Germany
5 Translational Neurology group, Wallenberg Neuroscience Center, BMC, Lund, Sweden
6 Systems Biology Center, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
7 Wayne State University, School of Medicine, Cancer Biology PhD Program, Detroit, Michigan, USA
Massimo Alessio, email:
Keywords: ADAM10 metalloprotease, colorectal carcinoma, immuno-proteomics, autoantibodies, prognosis
Received: April 12, 2016 Accepted: July 10, 2016 Published: August 10, 2016
A humoral immune response against aberrant tumor proteins can be elicited in cancer patients, resulting in the production of auto-antibodies (Abs). By serological proteome analysis we identified the surface membrane protein ADAM10, a metalloproteinase that has a role in epithelial-tumor progression and invasion, as a target of the immune response in colorectal cancer (Crc). A screening carried out on the purified protein using testing cohorts of sera (Crc patients n = 57; control subjects n = 39) and validation cohorts of sera (Crc patients n = 49; control subjects n = 52) indicated that anti-ADAM10 auto-Abs were significantly induced in a large group (74%) of colon cancer patients, in particular in patients at stage II and III of the disease. Interestingly, in Crc patients classified as stage III disease, the presence of anti-ADAM10 auto-Abs in the sera was associated with a favourable follow-up with a significant shifting of the recurrence-free survival median time from 23 to 55 months. Even though the ADAM10 protein was expressed in Crc regardless the presence of auto-Abs, the immature/non-functional isoform of ADAM10 was highly expressed in the tumor of anti-ADAM10-positive patients and was the isoform targeted by the auto-Abs. In conclusion, the presence of anti-ADAM10 auto-Abs seems to reflect the increased tumor expression of the immunogenic immature-ADAM10 in a group of Crc patients, and is associated with a favourable prognosis in patients at stage III of the disease.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.